Comparison of G1 Therapeutics Inc. (GTHX) and Provention Bio Inc. (NASDAQ:PRVB)

G1 Therapeutics Inc. (NASDAQ:GTHX) and Provention Bio Inc. (NASDAQ:PRVB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
G1 Therapeutics Inc. N/A 0.00 88.83M -2.57 0.00
Provention Bio Inc. N/A 0.00 32.54M -0.79 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of G1 Therapeutics Inc. and Provention Bio Inc.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
G1 Therapeutics Inc. 0.00% -28.3% -27.2%
Provention Bio Inc. 0.00% -103.2% -62.9%


G1 Therapeutics Inc.’s Current Ratio is 30.2 while its Quick Ratio is 30.2. On the competitive side is, Provention Bio Inc. which has a 32.9 Current Ratio and a 32.9 Quick Ratio. Provention Bio Inc. is better positioned to pay off short and long-term obligations compared to G1 Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors owned 86.5% of G1 Therapeutics Inc. shares and 6.2% of Provention Bio Inc. shares. 0.5% are G1 Therapeutics Inc.’s share owned by insiders. Competitively, Provention Bio Inc. has 14% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
G1 Therapeutics Inc. 13.68% 35.75% 12.76% -47.95% -49.4% 24.13%
Provention Bio Inc. -13.73% 24.38% 48.52% 11.39% 0% 98.87%

For the past year G1 Therapeutics Inc.’s stock price has smaller growth than Provention Bio Inc.


On 4 of the 6 factors Provention Bio Inc. beats G1 Therapeutics Inc.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.